by Peter Ciszewski | Dec 6, 2017
Ovid Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TAK-935/OV935 for the treatment of Dravet syndrome, a severe and rare form of childhood epilepsy that typically presents during the first year of...
by Peter Ciszewski | Nov 28, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer of Ovid Therapeutics, discusses the importance of investigating Ovid’s therapies in younger patients suffering from Fragile X and Angelman syndromes. Fragile X syndrome is a genetic condition that causes a...
by Peter Ciszewski | Nov 28, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, discusses OV101, a compound that was originally developed to treat insomnia, but is now being studed in Angelman and Fragile X syndromes. OV101 (gaboxadol) is believed to be the only delta...
by Peter Ciszewski | Nov 27, 2017
Sobi received approval from Health Canada for an oral suspension formulation of Orfadin (nitisinone). Orfadin is the first medicine approved in multiple countries globally for use in combination with dietary restriction of tyrosine and phenylalanine in the treatment...
by Peter Ciszewski | Nov 24, 2017
Melissa P. Wasserstein, MD, Chief of Pediatric Genetic Medicine at the Children’s Hospital at Montefiore, New York City, discusses the challenges of recruiting patients for rare disease clinical trials, including Nieman-Pick disease.
